Abstract Mutations of cardiac myosin binding protein-C (cMyBP-C) are inherited by an estimated 60 million people worldwide, and the protein is the target of several kinases. Recent evidence further suggests that cMyBP-C mutations alter Ca 2+ transients, leading to electrophysiological dysfunction. Thus, while the importance of studying this cardiac sarcomere protein is clear, preliminary data in the literature have raised many questions. Therefore, in this article, we propose to review the structure and function of cMyBP-C with particular respect to the role(s) in cardiac contractility and whether its release into the circulatory system is a potential biomarker of myocardial infarction. We also discuss future directions and experimental designs that may lead to expanding the role(s) of cMyBP-C in the heart. In conclusion, we suggest that cMyBP-C is a regulatory protein that could offer a broad clinical utility in maintaining normal cardiac function.
Introduction
Cardiac myofilament proteins, which form the functional unit of the sarcomere, coordinate heart function, while gene expression, assembly proteins, and signaling molecules regulate their structure and function. In this review, we discuss the structure and function of a cardiac thick filament protein, cardiac myosin binding protein-C (cMyBP-C). cMyBP-C protein was identified 40 years ago (Starr and Offer 1971) . Although it was later confirmed as a unique cardiac myosin binding protein located in the A-band of the cardiac sarcomere ( Fig. 1) , its structure and function remain elusive. Nonetheless, it has drawn considerable attention, as many studies have shown that genetic mutations in cMyBP-C gene (MYBPC3) cause hypertrophic cardiomyopathy (HCM). Recent reports suggest that cMyBP-C gene mutations have been inherited in more than 60 million people worldwide (Dhandapany et al. 2009; Barefield and Sadayappan 2010) , indicating the importance of understanding the role(s) of this protein in order to develop preventive clinical measures. Based on a review of the current literature, we believe it is time to redefine the structure and function of cMyBP-C.
of MyBP-C. Then, in the 1980s, cMyBP-C phosphorylation was associated with the development of increased systolic tension in the myocardium (Jeacocke and England 1980; England et al. 1983; Lim et al. 1985; Garvey et al. 1988; Schlender et al. 1987 Schlender et al. , 1988 Schlender and Bean 1991) . In fact, there are three different cMyBP-C isoforms specific for slow, fast, and cardiac muscles (Yamamoto and Moos 1983) . Cardiac MyBP-C was first shown to be important for the initial phase of skeletal muscle myofibrillogensis (Bahler et al. 1985; Kawashima et al. 1986; Saad et al. 1987) . Cardiac MyBP-C complementary deoxyribonucleic acid of chicken was first to be cloned, and domains were identified in 1995 (Yasuda et al. 1995) . Human cMyBP-C was then cloned, and the amino acid sequences were directly compared with the skeletal isoform, thus determining the uniqueness of cMyBP-C in which the C0 domain, phosphorylation motif, and the insertion of 28 residues in C5 domain are unique components ( Fig. 2) (Vaughan et al. 1992; Weber et al. 1993; Gautel et al. 1995; Yasuda et al. 1995; Carrier et al. 1997 ). In the 1990s, cMyBP-C was further identified as a target for protein kinase A (Gautel et al. 1995) , protein kinase C (Mohamed et al. 1998) , and Ca 2+ /calmodulin-dependent kinase (Gautel et al. 1995) . In mouse and human, cMyBP-C is expressed in both atrium and ventricle. Much later, using electron microscopy, Luther et al. (2008) first showed the arrangement of cMyBP-C in the C-zones of the A-band, demonstrating that 9 stripes transversely cross the thick and thin filaments with a length of 1.58±0.01 μm (Luther et al. 2008 ). This study further confirms that cMyBP-C arrangement is almost like skeletal MyBP-C, having 43-nm repeats (Luther et al. 2008 ), but cMyBP-C is a larger molecule (150 kDa), consisting of 12 domains, including the phosphorylation domain (M domain). Of the remaining 11 motifs, 8 are immunoglobulin (IgC2)-like and 3 are fibronectin (FN3) domains. Overall, cMyBP-C is different from the two skeletal isoforms by having an extra IgC2 domain (C0 domain) (Yasuda et al. 1995) , multiple phosphorylation motifs in the M-domain located in between C1 and C2 domains (Gautel et al. 1995; Mohamed et al. 1998; Yuan et al. 2006; Jia et al. 2010) , and an insertion of 28 novel residues within the C5 domain (Gautel et al. 1995) . Sequencespecific species differences in the P/A rich region are known to modulate actomyosin interactions ). The combination P/A sequences, with a preponderance of acidic residues, in the P/A linker suggest that this region could function as a modulator of thin filament interactions (Table 1) . However, its significance in terms of myofilament regulation and contractile function is unknown. Therefore, a systematic collaborative study at the structural, cellular, molecular, and functional levels should be performed to determine the functional roles of the novel insertion in the C5 domain, Pro-Ala-rich region, and cardiac-specific C0. The full-length cMyBP-C protein could be expressed and purified Fig. 1 Schematic structure of cardiac sarcomere and localization of cMyBP-C. a Cardiac sarcomere is the functional unit of cardiac muscle, which is defined as the region of myofilament between two Zlines. The distance between Z-lines, which is defined as sarcomere length, ranges from about 1.6 to 2.2 μM. The Z-band, I-band, A-band, and M-lines are marked. cMyBP-C localizes in the C-zone of the Aband on both side of the M-line. The sarcomere composed of thick and thin filaments. The thick filament proteins are myosin, cMyBP-C and myosin light chains. The thin filaments are composed of actin, α-tropomyosin and troponin complex such as cTnT, cTnI, and cTnC. Stretching the sarcomere increases cTnC's affinity for Ca 2+ , resulting in an increased tension development, which is referred as lengthdependent activation. Sarcomeric actin is the major component of the I-band. Myomesin in the M-band and cMyBP-C in the C-zone crosslink the myosin and titin. b an immunoelectron micrograph image of the rat cardiac sarcomere that is immunolabelled with anti-cMyBP-C antibodies (courtesy Pradeep K Luther, Imperial College, London, UK; Luther et al. 2008) . The cMyBP-C localizes at a series of nine transverse stripes (scale bar 200 nm) Fig. 2 Cardiac and skeletal MyBP-C isoforms and their variants. There are four isoforms of MyBP-C exits: one cardiac and two skeletal isoforms. The immunoglobulin and fibronectin type III domains are shown as rounded rectangle and hexagon, respectively. Cardiac MyBP-C differs from the two skeletal isoforms by having an extra C0 domain, phosphorylation motif at M domain and an insertion in C5 domain. A proline-alanine (P/A)-rich region is shown at the amino terminus. The smallest isoform is the MyBP-H, which possess significant homology with cMyBP-C carboxyl termini in vitro using the baculovirus expression system (Rybakova et al. 2011) , making it possible to study the three-dimensional structure of cMyBP-C in the future.
Since the precise arrangement of cMyBP-C in the sarcomere is unclear, the structural information is of little use in understanding the roles played by post-translational modification in modulating cMyBP-C interaction with actin and/or myosin. Two structural models are currently being discussed and tested: (1) the trimeric collar model (Moolman-Smook et al. 2002; Flashman et al. 2004 Flashman et al. , 2008 , and (2) the rod model of axial oriented arrangement (Squire et al. 2003) . Based on the in vitro binding studies (Flashman et al. 2008 ), the collar model suggests that three cMyBP-C molecules interact at the C5-C10 domains to form a collar-like structure around the core of the thick filament (Flashman et al. 2008 ). The rod model proposes that the C terminal domains of cMyBP-C interact along the axis of the thick filament with the N-terminal domains extended perpendicularly towards the thin filament (Squire et al. 2003) . Three-dimensional images of cMyBP-C captured by electron microscopy suggest that 3-4 domains of cMyBP-C form a rod-like structure by C terminal interaction along the axis of thick filament (Zoghbi et al. 2008) . While data supporting each model seem to conflict, both models suggest interaction with both thick and thin filament systems. However, the arrangement of cMyBP-C in the sarcomere is still a mystery and needs systematic investigation. X-ray diffraction studies (Squire et al. 2004; Palmer et al. 2004 Palmer et al. , 2011 Colson et al. 2007 Colson et al. , 2008 Jeffries et al. 2008; Farman et al. 2010 Farman et al. , 2011 and electron tomography (Luther et al. 2011) should advance our understanding of cMyBP-C structure and define its interaction regions. Importantly, NMR structural studies suggested that individual C0, C1, and C2 domains are like elongated rod particles, sufficient to reach thin filaments ). While one study has shown that the M-domain in cMyBP-C is a compact domain ), recent atomic force microscopy studies show that it is disordered (Karsai et al. 2011 ). However, the molecular structure and the interaction of the m-domain remain unknown.
cMyBP-C is critical for the normal cardiac function
The pathological consequences of MYBPC3 mutations are not fully described because C'-truncated cMyBP-C has not been found in cardiac tissue from affected HCM patients (Rottbauer et al. 1997; Moolman et al. 2000; Marston et al. 2009; van Dijk et al. 2009; Barefield and Sadayappan 2010) . This indicates that the truncated protein is either not expressed or is rapidly degraded. McConnell et al. (1999) generated a mouse model (MYBPC3 (t/t) ) that is homozygous for MYBPC3 truncated genes containing novel C' amino acids which disallow cMyBP-C incorporation into the sarcomere (McConnell et al. 1999 Berul et al. 2001) . MYBPC3 (t/t) mice display a null cMyBP-C background, but remain viable, exhibiting myocardial hypertrophy and decreased contractility. However, this mouse model was not a genetic model of cMyBP-C ablation, as it expresses detectable quantities of cMyBP-C protein. To test the hypothesis that cMyBP-C is essential for sarcomere assembly, structure, and function, the Moss laboratory generated a conventional cMyBP-C knockout mouse model by replacing exons 3-10 of MYBPC3 with a gene encoding neo resistance (Harris et al. 2002) . The homozygous knockout mice showed no detectable cDNA and protein of cMyBP-C. Interestingly, the ablation of cMyBP-C in the heart triggered cardiac hypertrophy and reduced diastolic and systolic function (Harris et al. 2002) . Otherwise, the knockout mice are viable and show regular sarcomeres, suggesting that cMyBP-C is not necessary for cardiac development and basic cardiac function (Harris et al. 2002) , but is essential for normal cardiac function. Basic cardiac function refers to regular contraction and continuous pumping of blood throughout the body and the lungs, whereas normal cardiac function refers to the defined diastolic and systolic hemodynamics, which are altered by cMyBP-C ablation.
In vitro studies showed that myocytes from cMyBP-C knockout mice have decreased myofilament Ca 2+ sensitivity of tension (Harris et al. 2002) . In addition, cMyBP-C ablation showed a defect in diastolic relaxation and myofilament Ca 2+ sensitivity . Strikingly, further studies showed that abrogation of cMyBP-C accelerates P/A proline-alanine, pI isoelectric point, MWt molecular weight in kilodalton (kDa); data show that the P/A region alone is acidic, compared to other domains a Removal of P/A (ΔP/A) either in C0-C3 or full-length increases the pI values, suggesting that the P/A-rich region is sufficient to alter the pI value of cMyBP-C. Residues and pI values are referred from the Uniprot O70468 and protein calculator v3.3, respectively stretch activation (Stelzer et al. 2006a ) and force development (Stelzer et al. 2006b ) in the knockout mouse model. Furthermore, protein kinase A (PKA)-mediated accelerated stretch activation response is completely absent in the cMyBP-C knockout mice, suggesting that cMyBP-C directly contributes to the PKA-mediated acceleration of the stretch activation response (Stelzer et al. 2006c ). Moreover, cMyBP-C phosphorylation may partially require the reduction of myofilament Ca 2+ sensitivity, followed by the β-AR stimulation and PKA activation . Next, when the knockout cMyBP-C mice were challenged with pressure overload, they failed to compensate for the increased load and showed a significant reduction in systolic and diastolic function, suggesting the importance of cMyBP-C for the maintenance of ventricular function and β-adrenergic-induced response (Brickson et al. 2007) . Synchrotron low-angle xray diffraction studies showed that the equatorial intensity ratio is greater in the cMyBP-C knockout myofibrils, compared to wild-type controls, without changing thick filament lattice spacings (Colson et al. 2007 ). These data indicate that cMyBP-C serves as a mechanical tether on myosin and acts as a structural restraint on myosin heads. Either phosphorylation or ablation of cMyBP-C releases such constraint on myosin, resulting in accelerating cardiac muscle force generation. Therefore, cMyBP-C is capable of regulating sarcomere structure and function.
cMyBP-C phosphorylation and its physiological significance
Cardiac contractility is subject to regulation by the β-adrenergic system. Activation of the β-adrenergic receptors (β-AR) induces chronotropic, lusitropic, and inotropic effects. Activated β-AR transduces its signal by activating adenylyl cyclase and, subsequently, cyclic AMP (cAMP)-mediated protein kinase activation, which promotes maximal myocardial performance. However, excessive sympathetic nervous system stimulation can cause heart failure (HF) and cell death (Talan et al. 2011) . One unique property of cMyBP-C is its multiple phosphorylation sites at Mdomain (Table 2) , which are absent in the skeletal muscle isoform. cMyBP-C phosphorylation is necessary for normal cardiac function (Sadayappan et al. 2005; Tong et al. 2008) and sufficient to protect the heart from the ischemic injury (Sadayappan et al. 2006) , under either α-or β-myosin heavy chain background ), suggesting that cMyBP-C phosphorylation is necessary for normal myocardial function, irrespective of myosin background, and that it can preserve cardiac function. The cMyBP-C protein has multiple phosphorylation sites within the Mdomain, such as Ser-273, Ser-282, Ser-302, and Ser-307 (Mouse, Uniprot ID 070468). The multiple phosphorylation sites are targeted by protein kinase A (Gautel et al. 1995; Mohamed et al. 1998) , protein kinase C (Mohamed et al. 1998; Xiao et al. 2007 ), CaMKII (Gautel et al. 1995; Sadayappan et al. 2011) , protein kinase D (Bardswell et al. 2010) , and ribosomal s6 kinase . In vitro studies show that PKA phosphorylates Ser-273, Ser-282, and Ser-302, whereas PKC only phosphorylates Ser-273 and Ser-302 (Mohamed et al. 1998 ). In addition, hierarchal phosphorylation patterns for cMyBP-C have been defined in vitro (Gautel et al. 1995) , where CaMKII phosphorylation at Ser-282 is a prerequisite for phosphorylation of the other two sites (Schlender and Bean 1991; Mohamed et al. 1998; McClellan et al. 2001; Sadayappan et al. 2011) . The data obtained from in vitro studies show that the ability of PKA and/or PKC to phosphorylate Ser-273 and Ser-302 is markedly reduced when Ser-282 is mutated, reducing subsequent phosphorylation (Gautel et al. 1995) . Phosphorylation of cMyBP-C at Ser-282 by CaMKII is also associated with myocardial stunning where β-AR activation is necessary to enhance contractility (Cheng et al. 2003; Yuan et al. 2006) . Deletion or mutation of Ser-282 decreased cMyBP-C total phosphorylation (Gautel et al. 1995; Cuello et al. 2011) , and in vitro studies demonstrated that sequential phosphorylation could take place Ser 282 (first) and Ser -302 (second). Strikingly, serine is required at 282 position to phosphorylate the Ser-302 site in vitro . However, the hierarchical effects of CaMKII phosphorylation in vivo remain to be systematically investigated .
The necessity of cMyBP-C phosphorylation for normal cardiac function at Ser-273, Ser-282, and Ser-302 sites was discovered using mouse models in which the phosphorylation sites were mutated to alanine, mimicking phospho-ablation, which resulted in the development of cardiac hypertrophy with decreased contractile function (Sadayappan et al. 2005; Tong et al. 2008) . Data showed that cMyBP-C is extensively phosphorylated under basal conditions (Sadayappan et al. 2005) . However, the level of cMyBP-C phosphorylation decreases in animal models during development of ischemia-reperfusion injury, HF, pathologic hypertrophy (Sadayappan et al. 2005) , myocardial stunning (Decker et al. 2005; Yuan et al. 2006) , and in patients with atrial fibrillation (El-Armouche et al. 2006), HF Jacques et al. 2008 ) and cardiomyopathies (Copeland et al. 2010) . Further studies have shown that cMyBP-C phosphorylation by PKA regulates myocardial function (Sadayappan et al. 2005 (Sadayappan et al. , 2006 Nagayama et al. 2007; and confers resistance to proteolysis and protection against ischemia-reperfusion injury (Sanada et al. 2004; Sadayappan et al. 2009 ). The degradation of cMyBP-C during ischemia-reperfusion injury also correlates well with contractile dysfunction (Decker et al. 2005; Sadayappan et al. 2006 ). Recent studies have further shown that cMyBP-C is readily releasable myofilament protein from cardiac sarcomeres and sensitive to proteolysis post-MI in a phosphorylation-dependent manner, such that cleavage of its N'-fragments can be detected in plasma (Govindan et al. 2012) . Altogether, these data suggest that cMyBP-C is a central target for signal transduction to regulate sarcomere structure and function .
Functional studies showed that the cMyBP-C phosphorylation patterns could apparently play important roles in regulating movement of the myosin head and the contractile characteristics of the myofilament. cMyBP-C phosphorylation promotes actin-myosin interaction by either relieving a structural constraint on myosin or reducing binding of cMyBP-C to the S2 region of myosin to allow closer proximity with actin (Flashman et al. 2004) . Consequently, phosphorylation of cMyBP-C increases cross-bridge cycling rate (Stelzer et al. 2006c (Stelzer et al. , 2007 Tong et al. 2008) . Thus, changing physiological conditions can cause phosphorylation of cMyBP-C to accelerate cardiac contractility. Dephosphorylated cMyBP-C inhibits actin-myosin interaction to slow cross-bridge cycling Rybakova et al. 2011; Ackermann and KontrogianniKonstantopoulos 2011b) . In contrast, phosphorylation of cMyBP-C releases its inhibition. Thus, cMyBP-C phosphorylation level can regulate the rate of cross-bridge attachment/detachment (Gautel et al. 1995; Kunst et al. 2000) . In 2004, Harris et al. (2004) demonstrated that binding of cMyBP-C to myosin S2 region is sufficient to alter myosin contractility and that phosphorylation of cMyBP-C directly influences myofilament Ca 2+ sensitivity. Using cMyBP-C knockout mouse hearts, studies showed that PKA-mediated phosphorylation of cMyBP-C directly activates contraction kinetics by accelerating the kinetics of myosin interaction with actin (Stelzer et al. 2006c ). Subsequently, in the same mouse model, data showed that phosphorylation of cTnI reduced the Ca 2+ sensitivity of force, whereas phosphorylation of cMyBP-C regulated cross-bridge rate and force development (Stelzer et al. 2007) . The cross-bridge kinetics of myocardial force generation is accelerated by β-adrenergic stimulation, partially via PKA-mediated phosphorylation of sarcomeric proteins. The working hypothesis was that phosphorylation of cMyBP-C modulates myosin cross-bridges to move radially toward actin by releasing its C1-C2 domain constraint, thereby allowing myosin S2 to move faster towards actin to accelerate contractile rate (Weisberg and Winegrad 1996; Colson et al. 2008) . The same situation could be mimicked by ablating cMyBP-C (Colson et al. 2007) , confirming that cMyBP-C phosphorylation untethers cross-bridges during β-adrenergic stimulation and accelerates contraction. Studies using the cMyBP-C phospho-ablated mouse models demonstrated that loss of cMyBP-C phosphorylation leads to cardiac dysfunction and development of cardiac hypertrophy (Sadayappan et al. 2005; Tong et al. 2008) . In contrast, cMyBP-C phospho-mimetic mouse models showed normal cardiac function. In conclusion, cMyBP-C phosphorylation is necessary and sufficient for regulating myosin-actin interactions, normal cardiac function, and accelerated force generation during β-adrenergic stimulation. The mode of interaction and domains in the cMyBP-C that directly regulates contraction are yet to be determined in the future studies.
Gene defects in cMyBP-C cause hypertrophic cardiomyopathy and alter Ca 2+ transients
Clinical conditions
A common cause of HF is dilatation or hypertrophy and impaired contraction of one or both ventricles of the heart in the absence of significant coronary artery disease. These disorders are termed dilated (DCM) or hypertrophic (HCM) cardiomyopathy. Multiple mutations in multiple sarcomeric proteins are causative for HCM ). The high morbidity and mortality associated with cardiomyopathy underscores the need for a better understanding of the molecular events that ultimately lead to HF. HCM is a primary myocardial disorder with heterogeneous morphological, functional, and clinical features (Maron et al. 2001) . Discovering the function of cMyBP-C is also important from a clinical point of view, as the protein is frequently involved with the pathophysiology of HCM, which affects 1% of the world's population (Watkins et al. 1995; Bonne et al. 1998; Dhandapany et al. 2009 ). Harris et al. (2011) recently reviewed the roles of all the thick filamentassociated proteins and their known mutations that cause hypertrophic cardiomyopathies. Cardiac β-myosin heavy chain is first on the list, while cMyBP-C is second with 197 mutations already determined . Mutations in MYBPC3 are found in 35% of all cardiomyopathy cases showing symptoms such as left ventricular systolic dysfunction and/or cavity dilation Barefield and Sadayappan 2010) . Interestingly, numerous nonsense mutations in cMyBP-C lead to Cterminal truncated polypeptides, which lack titin and light meromyosin of myosin binding sites. Although missense mutations have also been reported, the degree of incorporation and steady state levels of these mutants are unclear, and both haploinsufficiency and the presence of a "poison peptide" have been invoked for the different MYBPC3 mutations (Redwood et al. 1999 ). Out of 197 MYBPC3 mutations, 70% are C'-truncations and are never detected by western blot in myocardial tissue from HCM patients. Understandably, C'-truncations of MYBPC3 are unable to incorporate in the sarcomere, as they lack key myosin-binding residues. As a result, homozygous C'-truncations of MYBPC3 show cMyBP-C null mouse hearts which resemble a homozygous knockout of cMyBP-C. Conversely, asymptomatic heterozygous mouse carriers show 100% cMyBP-C stoichiometry without any cardiac phenotype , suggesting that, under normal conditions, haploinsufficiency is not causative for the HCM phenotype (Fig. 3) . Thus, downstream mechanisms of longitudinal haploinsufficiency under stress remains to be elucidated (Schlossarek et al. 2011b ). Degradation of truncated and mutant cMyBP-C has been shown to be associated with the ubiquitin-proteasome system (Sarikas et al. 2005; Schlossarek and Carrier 2011) , and nonsense-mediated mRNA decay (Vignier et al. 2009; Carrier et al. 2010) pathways, which are still controversial, provide therapeutic avenues (Schlossarek et al. 2011a; James and Robbins 2011) .
Animal models
Various cMyBP-C transgenic mouse models have demonstrated the importance of cMyBP-C for long-term integrity of sarcomeric structure and its involvement in normal contractility of the heart (Yang et al. 1998 (Yang et al. , 1999 McConnell et al. 1999; Carrier et al. 2004) . Cardiac MyBP-C knockout mice demonstrate that cMyBP-C is not essential for survival, although its absence does causes hypertrophic cardiomyopathy (Harris et al. 2002; Carrier et al. 2004) . cMyBP-C mouse models which lack either the myosin (Yang et al. 1999) or the myosin and titin binding sites (Yang et al. 1998; Yang et al. 2001 ) have been generated to study the pathophysiological effects of truncated cMyBP-C proteins. Carrier et al. (2004) created a transcriptional knockout of cMyBP-C that results in asymmetric septal hypertrophy at 10-11 months of age (Vignier et al. 2009 ). In addition, a knockin mouse model that carries N-terminal-shortened cMyBP-C shows no significant ultrastructural changes of the heart and appears to have a normal lifespan (Witt et al. 2001) . Since these mouse models (McConnell et al. 1999; Yang et al. 1999 Yang et al. , 1998 Yang et al. , 2001 Witt et al. 2001; Carrier et al. 2004 ) focus on characterizing homozygous MYBPC3 transgenic animals, the results do not correlate to the heterozygous genotype normally found in the human population. Young human heterozygote carriers were mostly asymptomatic or mildly symptomatic, but ∼90% of the heterozygote carriers over 50 years of age were mildly Fig. 3 Schematic diagram illustrates how haploinsufficiency of cMyBP-C respond to cardiac insult. Prolonged stress leads to decreased cMyBP-C phosphorylation, which allows increased proteolysis and reduction of cMyBP-C levels in the sarcomere. In haploinsufficient situations, a single wild-type MYBPC3 gene is not able to fully compensate for the loss of cMyBP-C. This leads to the disease phenotype associated with HF symptomatic (Dhandapany et al. 2009 ). These data clearly suggest that heterozygous cMyBP-C truncation itself is not sufficient to mediate myocardial dysfunction and pathology causing HCM. Additional factors, such as cardiac stress, injury, and compound mutation in other contractile genes, could add to the phenotype for the disease severity (Waldmuller et al. 2003 ).
MYBPC3 gene mutation and cardiac arrhythmia
Cardiac arrhythmia may lead to HF in patients with HCM. Generally, altered expression of ion channels and Ca
2+
handling proteins causes abnormal Ca 2+ handling and result in HF (Tomaselli and Marban 1999) . Mutations in contractile proteins cause altered Ca 2+ handling and result in HF (Gao et al. 1999; Guinto et al. 2009; Manning et al. 2011; Tardiff 2011) . Recent studies show that cMyBP-C mutation is related to the development of arrhythmias (Bahrudin et al. 2011) . For example, patients with E334K mutation in MYBPC3 gene exhibited cardiac arrhythmias (Bahrudin et al. 2008 ). This report is consistent with mouse model results showing that MYBPC3 mutations are likely to induce ventricular arrhythmias , which could be explained by proteasome inhibition by the mutant cMyBP-C proteins, leading to the accumulation of ion channel and/ or Ca 2+ -handling proteins and resulting in electrophysiological dysfunction (Bahrudin et al. 2008; Vignier et al. 2009; Carrier et al. 2010 ). However, the direct relationship between contractile protein dysfunction and altered Ca 2+ transients remains a question requiring systematic investigation.
cMyBP-C is not only the myosin binding protein
When cMyBP-C was discovered, it was first determined as a contaminant of myosin preparation (Starr and Offer 1971) and later defined as a myosin binding protein of thick filament (Fig. 4) . Originally, F-actin binding properties of skeletal MyBP-C were reported in late 1970s, proposing that the length of the skeletal MyBP-C is sufficient to reach thin filaments and interact with F-actin (Moos et al. 1978; Moos 1981; Ackermann and Kontrogianni-Konstantopoulos 2011a, b) . Then, the binding of skeletal MyBP-C to regulated actin filaments in the presence or absence of calcium was determined, suggesting that binding of skeletal MyBP-C to F-actin depends on the state of F-actin filament, not necessarily calcium (Yamamoto 1986 ). In the presence of Ca 2+ , it was further discovered that cMyBP-C regulates actin filaments in a Ca 2+ -dependent manner (Yamamoto 1986) . Next, the C0 domain was shown to directly bind with actin (Kulikovskaya et al. 2003 ) and possibly the P/A region, too (Squire et al. 2003) . It is clear, based on this evidence, that cMyBP-C binds to actin, but questions about the location and number of binding sites remained. Table 3 shows the interacting ligands of cMyBP-C. The potential binding N-terminal region of cMyBP-C was determined initially by neutron scattering studies . Then, two actin-binding sites, C1 and M domains, in cMyBP-C at the N-terminal region were reported (Shaffer et al. 2009b) . Binding of the M-domain is phosphorylationdependent. In agreement with Kulikovskaya et al. (2003) , this study further confirms that the C0 domain binds with Factin. In total, three regions of cMyBP-C bind with F-actin. However, the relative binding affinity of the C0 domain to actin was less than C1-C2 (Shaffer et al. 2009b ). The binding region of the M-domain with F-actin got attention (Kensler et al. 2011; Mun et al. 2011; Orlova et al. 2011 ; Fig. 4 Schematic structure of cMyBP-C domain and interaction regions with myosin. The IgI and fibronectin type III domains are shown as rounded rectangle and hexagon, respectively. The m domain is represented as oval shape, which is flanked by domains C1 and C2. The cardiac specific domains, C0, phosphorylation motifs within the M-domain and an insertion within domain C5 are shown in light red color. Interacting regions with titin and myosin subfragment 2 (S2), light meromyosin (LMM), regulatory light chain (RLC) and actin are indicated at their sites of interaction. cMyBP-C interacts with actin at multiple sites. Three stars indicate the position of phosphorylation sites of Ser-273, Ser-282, and Ser-302. Phosphorylation of these sites regulates the interaction of C1-m-C2 domain of cMyBP-C with myosin S2 region. Dimerization of domains C5 and C7 with C8 and C10, respectively, are indicated, which is critical for cMyBP-C arrangement around the thick filament. cMyBP-C interacts with myosin S2 and LMM at its C-terminal and N-terminal sites. Interacting with LMM is critical for cMyBP-C stability, whereas C'-terminal interaction is regulated by its phosphorylation sites, Ser-273, Ser-282, and Ser-302, marked as star, with S2 to regulate myosin function. Subfragment 1 (S1), regulatory light chain (RLC) and essential light chain of myosin heavy chain are indicated. In addition, the proline-alanine (P/A) rich region and calpain-targeted site (CTS) are marked. At the bottom, immunofluorescence staining of cMyBP-C (green) with anti-cMyBP-C 2-14 antibodies shows the striation pattern of cMyBP-C in the adult sarcomere Lu et al. 2011; Howarth et al. 2012) , because it can reach both myosin and actin in a phosphorylation dependentmanner (Razumova et al. 2006; Shaffer et al. 2009b ). In contrast to these studies, Rybakova et al. (2011) recently showed that cMyBP-C interacts with F-actin via a single site, which is localized in C6-C10 domains, whereas binding regions of the C0, C1, M, C0-C4, and C0-C5 domains are weak binding sites without saturation. Furthermore, this study rejects the hypothesis that the P/A-rich region of cMyBP-C has appreciable affinity with F-actin. However, a recent study using the laser trap assay demonstrates that the first 17 residues of M-domain are sufficient to interact with F-actin and alter acto-myosin motion generation (Weith et al. 2012 ). In conclusion, cMyBP-C is able to interact with F-actin, but it is not clear which binding region is critical for decorating F-actin and modulating contractile function in vivo. Studies using cMyBP-C fragments in vitro should be considered nonphysiological, as both cMyBP-C and actin are sticky molecules. Systematic mutation studies are required in vivo to determine the actin-binding properties of cMyBP-C.
cMyBP-C is a potential biomarker for myocardial infarction
Recently, cMyBP-C release into the circulatory system has been established, proposing that the amount of cMyBP-C present in the blood is directly proportional to the level of myocardial injury (Govindan et al. 2012) . cMyBP-C is a substrate for calpains , and dephosphorylation renders cMyBP-C more susceptible to proteolysis during ischemia-reperfusion injury (Sadayappan et al. 2006) . Such proteolysis leads to the release of cMyBP-C and its fragments into the blood (Fig. 5) . A predominant fragment of cMyBP-C, 40 kDa, was identified as an early-release fragment cleaved within a sequence of amino acid residues called the calpain-targeted site (272-TSLAGAGRRTS-282) Govindan et al. 2012) . The cleavage occurs within the PKA phosphorylation motif in a phosphorylation-dependent manner, supporting the hypothesis that cMyBP-C phosphorylation is resistant to proteolysis, while its dephosphorylation is sensitive to proteolysis. Strikingly, the amount of plasma cMyBP-C was several-fold higher than the normal healthier controls in patients with myocardial infarction (Govindan et al. 2012) , suggesting a In vitro studies such as pull-down, co-immunoprecipitation and cosedimentation assays were performed to determine the interaction of the cMyBP-C domain with its ligands. However, future studies should prove these interactions in vivo F-actin filament-actin, RLC regulatory light chain, Myosin S2 sub-fragment 2 of myosin heavy chain Fig. 5 Elevated levels of cMyBP-C in a plasma sample of postischemia-reperfusion injury. Representative western blot using anticMyBP-C antibodies shows higher levels of cMyBP-C and its fragments in plasma after ischemia-reperfusion injury in normal mice compared with sham operated controls. After the removal of 12 abundant plasma proteins including albumins, different concentrations of plasma (5, 10, and 15 μg) proteins were resolved and western blot analysis was performed with anti-cMyBP-C 2-14 antibodies. Results show the predominant appearance of cMyBP-C and its fragments in the circulatory system, suggesting a potential role of biomarker for myocardial injury. The lowest 40-kDa fragment is known to be cleaved by calpains, a Ca 2+ -activated protease that is activated during myocardial injury new role for cMyBP-C as a biomarker for myocardial infarction (Baker et al. 2010; Govindan et al. 2012) . However, the time course of cMyBP-C cleavage and release or its sensitivity, specificity, and half-life in plasma have not yet been determined. Other questions remain to be resolved in the future. These include, for example, what phosphatase(s) act (s) on cMyBP-C and whether cMyBP-C activity is increased during I-R injury and cardiomyopathies.
cMyBP-C is a regulatory protein, not a structural protein Recent arguments have centered on the question as to whether cMyBP-C is a regulatory or structural protein. Based on the literature and available data, we propose that cMyBP-C is foremost a regulatory protein, rather than a structural protein.
Unlike other sarcomere proteins, cMyBP-C belongs to the immunoglobulin (IgI) super-family of intracellular muscle proteins, which are cell-surface and soluble proteins involved in the recognition, binding, and adhesion processes on the cell membrane, such as cell-surface antigen receptors and intracellular muscle proteins (Harpaz and Chothia 1994) . The other sarcomere regulatory IgI family proteins are telokin (Yoshikai and Ikebe 1992) , myomesin (Eppenberger et al. 1981; Steiner et al. 1998) , kettin (Lakey et al. 1993) , and the giant protein titin (Labeit et al. 1992) to which the skeletal MyBP-C isoform (Furst et al. 1992 ) and cMyBP-C isoform bind (Koretz et al. 1993) . The IgI domain consists of a sandwich of two β-sheets held together by a disulfide bond. There are two main types of IgI domain: C and V domains in which IgV domains (9 beta strands) are generally longer than IgC domains (7 beta strands). cMyBP-C predominantly consists of C domains. IgI superfamily proteins are thought to be involved in the regulation of interactions between cells. Similar IgI superfamily proteins are found in neurons with fibronectin domains (Takai and Nakanishi 2003) . Therefore, it is possible that longitudinal arrangement of cMyBP-C in the C-zone of Aband connects thin and thick filaments across the sarcomeres and synchronizes them functionally (Einheber and Fischman 1990) . However, while cMyBP-C is not essential for sarcomere assembly and structure, it is necessary for accelerated force generation and normal cardiac function (Harris et al. 2002) . cMyBP-C can be considered to be a structural protein based on its stoichiometry, arrangement, and localization on the sarcomere. In addition, C-terminal truncated cMyBP-C proteins are unable to incorporate into the sarcomere (Moolman et al. 2000) . Structural proteins are considered to be essential for cardiac function, and knockout of these proteins in mice leads to embryonic lethality, such as α-myosin (Jones et al. 1996) , cardiac α-actin (Kumar et al. 1997) , cTnI (Huang et al. 1999) , cTnT (Ahmad et al. 2008) , and α-TM (Rethinasamy et al. 1998 ). However, cMyBP-C knockout mice are viable and live for more than 2 years ). Unlike other myofilament proteins which need high salt buffer to solubilize, we recently determined that cMyBP-C is an easily soluble and releasable protein from the sarcomere (Govindan et al. 2012 ). In addition, cMyBP-C is a central target for several kinases, phosphatases, and proteases. Based on this evidence, we propose that cMyBP-C is primarily a regulatory protein, not a structural protein.
Future direction
cMyBP-C is a superfamily protein of IgI which contains an additional Ig domain at the N'-region, C0, and a P/A linker connecting the C0 and C1 domains, compared to the skeletal isoforms. cMyBP-C phosphorylation is known to modulate cardiac contractility. The phosphorylation sites reside in the M-domain, which is located between the C1 and C2 modules and involved in conformational changes central to modulating thick-thin filament interactions (Howarth et al. 2012) . Phosphorylation of the M-domain regulates cMyBP-C interaction with myosin in a dynamic manner. If the Mdomain and the associated phosphorylation sites are critical to actin binding, then the absence of these phosphorylation sites in skeletal MyBP-C implies that it binds to actin in other regions of skeletal MyBP-C. Another possibility is that skeletal and cardiac actin may bind skeletal and cardiac MyBP-C in different regions, respectively, even though their amino acid sequences are very similar. Further structural studies are required to address these points.
Directly targeting the contractility of the cardiac sarcomere is now a focus of drug development, bypassing all the signaling ligands, and could have significant advantages in more precisely targeting a therapeutic action. In particular, direct activation (Cleland et al. 2011; ) and inhibition of myosin (Zhao et al. 2011 ) are novel therapeutic approaches to ameliorate HF and hypertension, respectively. Dephosphorylation of cMyBP-C results in a shorter myosin cross-bridge lifetime, thus deactivating myosin and, in turn, reducing cardiac contractility (Palmer et al. 2011) . Therefore, we hypothesize that inhibition of myosin at its S2 region during prolonged β-AR stimulation through cMyBP-C interaction is a potential therapeutic approach. Overall, understanding the molecular consequences of cMyBP-C structure, post-translational modification, and function is critical to the design of new agents to protect the heart and improve cardiac function after HF.
